MX2019014597A - Inhibidores de pirazolopirimidina de pde9. - Google Patents

Inhibidores de pirazolopirimidina de pde9.

Info

Publication number
MX2019014597A
MX2019014597A MX2019014597A MX2019014597A MX2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A
Authority
MX
Mexico
Prior art keywords
pyrazolopyrimidine
present
compounds
pde9
pde9 inhibitors
Prior art date
Application number
MX2019014597A
Other languages
English (en)
Inventor
Raghavan Subharekha
Arasappan Ashok
Tyagarajan Sriram
Li Derun
M Cox Jason
S Debenham John
Guo Zhuyan
He Jiafang
Hussain Zahid
Lai Zhong
Meng Dongfang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019014597A publication Critical patent/MX2019014597A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de pirazolopirimidina que pueden ser útiles como agentes terapéuticos para el tratamiento de trastornos asociados con la fosfodiesterasa 9 (PDE9). La presente invención también se refiere al uso de dichos compuestos para tratar enfermedades cardiovasculares y cerebrovasculares, tales como hipertensión, enfermedad renal crónica e insuficiencia cardíaca, y trastornos neurológicos y psiquiátricos, tales como esquizofrenia, psicosis o enfermedad de Huntington, y los asociados con hipofunción estriatal o disfunción de los núcleos basales.
MX2019014597A 2017-06-08 2018-06-06 Inhibidores de pirazolopirimidina de pde9. MX2019014597A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516903P 2017-06-08 2017-06-08
US201862665840P 2018-05-02 2018-05-02
PCT/US2018/036172 WO2018226771A1 (en) 2017-06-08 2018-06-06 Pyrazolopyrimidine pde9 inhibitors

Publications (1)

Publication Number Publication Date
MX2019014597A true MX2019014597A (es) 2020-02-05

Family

ID=62779024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014597A MX2019014597A (es) 2017-06-08 2018-06-06 Inhibidores de pirazolopirimidina de pde9.

Country Status (13)

Country Link
US (2) US10934294B2 (es)
EP (1) EP3634964B1 (es)
JP (1) JP2020523309A (es)
KR (1) KR20200013758A (es)
CN (1) CN111051308A (es)
AU (1) AU2018281131B2 (es)
BR (1) BR112019025813A2 (es)
CA (1) CA3064938A1 (es)
MA (1) MA53841A (es)
MX (1) MX2019014597A (es)
RU (1) RU2019144010A (es)
TW (1) TW201902898A (es)
WO (1) WO2018226771A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523309A (ja) * 2017-06-08 2020-08-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ピラゾロピリミジンｐｄｅ９インヒビター
WO2020123271A1 (en) * 2018-12-12 2020-06-18 Merck Sharp & Dohme Corp. Cyclobutyl pyrazolopyrimidine pde9 inhibitors
US20220017526A1 (en) * 2018-12-12 2022-01-20 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
CA3132895C (en) 2019-03-08 2024-05-14 Transthera Sciences (Nanjing), Inc. Uses of phosphodiesterase inhibitors
WO2021253180A1 (en) * 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
CN114773256B (zh) * 2022-03-23 2024-05-03 中国农业大学 一种4-氰基哌啶的合成方法
CN117582909B (zh) * 2024-01-19 2024-04-02 天津凯莱英医药科技发展有限公司 一种连续生产5-单硝酸异山梨酯的系统和方法
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE960441L (en) 1988-12-27 1990-06-27 Takeda Chemical Industries Ltd Guanidine derivatives, their production and insecticides
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2002009713A2 (de) 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
JP2005508978A (ja) 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
CA2612176C (en) 2005-06-14 2015-02-17 Aska Pharmaceutical Co., Ltd. Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
JP5193866B2 (ja) 2006-08-08 2013-05-08 あすか製薬株式会社 キナゾリン誘導体
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
MX2009011830A (es) 2007-05-11 2009-11-13 Pfizer Compuestos amino-heterociclicos.
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
AR077859A1 (es) 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
UA110347C2 (uk) * 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
EP2669270B1 (en) 2011-01-28 2018-01-03 Sato Pharmaceutical Co., Ltd. Indole-related compounds as urat1 inhibitors
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN106905324B (zh) 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
KR101706216B1 (ko) 2012-04-03 2017-02-13 한화테크윈 주식회사 고밀도 삼차원 영상 재구성 장치 및 방법
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017019723A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone pde9 inhibitors
WO2017019724A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone pde9 inhibitors
US10370337B2 (en) 2015-07-29 2019-08-06 Merck, Sharp & Dohme Corp. Oxy-cyanoquinolinone PDE9 inhibitors
JP2020523309A (ja) * 2017-06-08 2020-08-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ピラゾロピリミジンｐｄｅ９インヒビター

Also Published As

Publication number Publication date
KR20200013758A (ko) 2020-02-07
CA3064938A1 (en) 2018-12-13
EP3634964B1 (en) 2022-02-23
RU2019144010A (ru) 2021-07-13
US20180354955A1 (en) 2018-12-13
CN111051308A (zh) 2020-04-21
JP2020523309A (ja) 2020-08-06
MA53841A (fr) 2021-09-22
BR112019025813A2 (pt) 2020-07-07
US20200140445A1 (en) 2020-05-07
AU2018281131A1 (en) 2019-12-05
US11028092B2 (en) 2021-06-08
AU2018281131B2 (en) 2022-01-20
RU2019144010A3 (es) 2021-10-01
EP3634964A1 (en) 2020-04-15
WO2018226771A1 (en) 2018-12-13
US10934294B2 (en) 2021-03-02
TW201902898A (zh) 2019-01-16

Similar Documents

Publication Publication Date Title
TN2014000070A1 (en) Pyrimidine pde10 inhibitors
MX2017011935A (es) Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2).
WO2012044562A3 (en) Pyrazolopyrimidine pde10 inhibitors
WO2012044561A3 (en) 2-alkoxy pyrimidine pde10 inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
WO2012054366A3 (en) Substituted amino-triazolyl pde10 inhibitors
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
AU2020288559A8 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
EA201190303A1 (ru) ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
MY193511A (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
PH12018502378B1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
SA520420768B1 (ar) مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية
WO2014150114A8 (en) Substituted pyridizinone derivatives as pde10 inhibitors
EP3454860A4 (en) 2-ANILINOPYRIMIDINE DERIVATIVES AS THERAPEUTIC ACTIVE SUBSTANCES FOR THE TREATMENT OF BRAIN CANCER
MXPA05012081A (es) Derivados de pirimidina sustituidos.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
ZA202308795B (en) Pro drugs of pde10 compounds
AR112073A1 (es) Inhibidores de pirazolopirimidina de pde9
ECSP14013268A (es) Inhibidores de pde10 de pirimidina
WO2024050061A3 (en) Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, composition, methods for treating neurological and psychiatric disorders